

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 19.06.2020

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Friday, 19th June, 2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Respected Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Friday, the 19th day of June, 2020, which commenced at 04:00 P.M. and concluded at 05:30 P.M. at the corporate office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) *inter-alia*, transacted the following business:

1. Approved the Audited Financial Results of the company for the quarter and year ended on 31st March, 2020 along with Statement of Assets and Liabilities as on 31st March, 2020 and statement of cash flow for the year ended on 31st March, 2020 (Enclosed herewith).
2. Took on record the Auditor's Report (with unmodified opinion) on the Financial Results of the Company for the quarter and year ended on 31st March, 2020 (Enclosed herewith).

Declaration in compliance with Regulation 33(3)(d) of Listing Regulations, read with SEBI Circular CIR/CFO/CMD/56/2016 dated May 27, 2016 is also enclosed herewith.


TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 22nd June, 2020 for the Directors and Key Managerial Personnel/ Designated Employees/ Connected Persons of the Company.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR SARDA PROTEINS LTD
For SARDA PROTEINS LTD


AMIT KUMAR MODI Secretary
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: 29371

Encl: a/a
Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2020 (Audited)	31.12.2019 (Unaudited)	31.03.2019 (Audited)	31.03.2020 (Audited)	31.03.2019 (Audited)
I	Revenue from operation					
II	Other Income	188.61	141.86	212.46	540.03	714.51
III	Total Revenue (I+II)	1.98	1.98	7.22	8.02	10.15
IV	Expenses	190.59	143.84	219.68	548.05	724.66
	Cost of Material Consumed	-	-	-	-	-
	Purchase of Stock-in-Trade	-	-	-	-	-
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	174.39	130.30	205.73	512.69	659.65
	Employee Benefit Expenses	-	-	-	-	42.82
	Finance cost	0.23	2.44	3.33	9.06	18.35
	Depreciation and Amortisation Expenses	0.18	-	0.20	0.21	0.20
	Other expenses	0.08	-	0.23	0.33	0.00
	Total Expenses	2.28	1.50	1.66	8.72	11.47
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	177.16	134.24	211.15	531.01	734.39
VI	Exceptional Items	13.43	9.60	8.53	17.04	(8.73)
VII	Profit/(Loss) before extraordinary items and tax (V-VI)	13.43	9.60	8.53	17.04	(8.73)
VIII	Extraordinary Items	-	-	-	-	-
IX	Profit/(Loss) Before tax (VII-VIII)	13.43	9.60	8.53	17.04	(8.73)
X	Tax Expense:					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	2.66	-	-	2.66	-
XI	Profit/(Loss) for the period from continuing operations (VII-VIII)	11.09	-	6.61	11.09	3.61
XII	Profit/(Loss) for the period from discontinuing operations	(0.32)	9.60	1.92	3.29	(12.34)
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV	Profit/(Loss) for the period (XI+XIV)	(0.32)	9.60	1.92	3.29	(12.34)
XVI	Other Comprehensive Income	-	-	-	-	-
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI)(Comprising Profit (Loss) and other comprehensive income for the period)	(0.32)	9.60	1.92	3.29	(12.34)
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59	172.59
XVIII	Earnings per Equity Share (For discontinued and continuing Operations)					
	(1) Basic	(0.02)	0.56	0.11	0.11	(0.71)
	(2) Diluted	(0.02)	0.56	0.11	0.11	(0.71)



on behalf of the Board
 Sarda Proteins Ltd
For SARDA PROTEINS LTD.

Deepak Datta (DIN: 015142RJ1991PLC006353)
 Managing Director

Place: Jaipur
 Date: 19-Jun-2020

UDIN: 20072 BS4 AAAAAM5192

STATEMENT OF ASSETS AND LIABILITIES AS ON MARCH 31, 2020

Particulars		Amount in Rs. Lakhs	
		Year ended 31.03.2020 (Audited)	Year ended 31.03.2019 (Audited)
A. ASSETS			
1	Non-Current Assets		
	a) Property, Plant and Equipment		
	b) Capital work in progress	0.59	1.77
	c) Investment Property		
	d) Goodwill		
	e) Other Intangible Assets		
	f) Intangible Assets under Development		
	g) Biological Assets other than bearer plants		
	h) Financial Assets		
	i) Investments		
	ii) Trade Receivables	0.13	0.13
	iii) Loans		
	iv) Deferred Tax Assets (net)	0.01	0.01
	j) Other non-current Assets	29.82	40.92
2	Current Assets	0.21	0.22
	a) Inventories		
	b) Financial Assets		
	i) Investments		
	ii) Trade Receivables		
	iii) Cash and Cash Equivalents	83.43	71.94
	iv) Bank Balances and other than (iii) above	10.24	6.96
	v) Loans		
	v) Others	90.69	97.40
	c) Current Tax Assets (net)		
	d) Other Current Assets		
	Total Assets	215.14	219.49
B. EQUITY AND LIABILITIES			
1	Equity		
	a) Equity Share Capital		
	b) Other Equity	250.45	250.45
2	Liabilities	(40.52)	(43.81)
	Non current Liabilities		
	a) Financial Liabilities		
	i) Borrowings		
	ii) Trade Payables		
	A) Total Outstanding dues to MSEs		
	B) Total Outstanding dues to Creditors other than MSEs		
	iii) Other Financial Liabilities		
	b) Provisions		
	c) Deferred Tax Liabilities (net)	1.01	0.95
	d) Other Non Current Liabilities		
	Current Liabilities		
	a) Financial Liabilities		
	i) Borrowings		
	ii) Trade Payables		0.73
	A) Total Outstanding dues to MSEs		
	B) Total Outstanding dues to Creditors other than MSEs		
	iii) Other Financial Liabilities		
	b) Other Current Liabilities		
	c) Provisions	4.20	3.13
	d) Current Tax Liabilities (net)		
	Total Equity and Liabilities	215.14	219.49



on behalf of the Board
 Sarda Proteins Ltd
 For SARDAPROTEINS LTD

Deepak Datta (DIN: 01060001)
 Managing Director

Place Jipur
 Date: 19-Jun-2020


UDIN: 20072854AAAAAM5192

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2020

Particulars		Amount in Rs. Lakhs	
		Year ended 31.03.2020 (Audited)	Year ended 31.03.2019 (Audited)
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before Tax and Extraordinary Items			
A. ADJUSTMENT FOR		17.05	(8.74)
Depreciation			
Interest Received		0.35	0.90
Profit on Sale of Investment		(8.02)	(7.22)
Dividend		-	(2.93)
(Profit)/Loss on sale of Fixed Assets		-	-
Interest Paid		0.01	-
		0.21	0.20
Operating Profit/(Loss) before Working Capital Charges		9.58	(17.79)
ADJUSTMENT FOR			
Trade and other Receivables		(4.66)	(82.48)
Inventories		-	42.99
Trade & other Payables		(6.90)	(1.36)
Cash Generated from Operations		(1.98)	(58.64)
Direct Taxes Paid		2.66	-
Net Cash from Operating Activities		(4.64)	(58.64)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital Expenditure		-	-
Sale of Fixed Assets		-	-
Profit/(Loss) on sale of Fixed Assets		0.84	-
Profit on sale of Investment		-	2.93
Sale of Investment		-	1.18
Interest Received		8.02	7.22
Dividend Received		-	-
Net Cash Received from Investing Activities		8.86	11.33
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Long Term Borrowings		-	-
Proceeds from Short Term Borrowings		(0.73)	0.73
Interest Paid		(0.21)	(0.20)
Net Cash Inflow/(Outflow) from Financing Activities		(0.94)	0.53
Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		3.28	(46.77)
Cash & Cash Equivalents (Opening)		6.96	53.74
Cash & Cash Equivalents (Closing)		10.24	6.96

Notes:

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 19th June 2020
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products"
- No Investor Complaints were received during the quarter ended 31-Mar-2020 nor any pending as on 01-Apr-2020
- The figures for the last quarter are the balancing figures between the audited figures of the financial years ended and the published results upto the third quarter of the respective financial years
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period
- The COVID-19 had not majorly affected operations of the company during last year, as the lock down in the country started at the month end of March 20



on behalf of the Board
 Sarda Proteins Ltd
For SARDA PROTEINS LTD.

Deepak Datta (DIN: 01633411)
 Managing Director

Place: Jaipur
 Date: 19-Jun-2020

UDIN: 20072854AAAAAM5192



Khetawat Agarwal & Co.
Chartered Accountants

Independent Auditor's Report

Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Sarda Proteins Ltd.

We have audited the quarterly financial results of **Sarda Proteins Ltd.** for the quarter ended March 31, 2020 and the year to date results for the period April 01, 2019 to March 31, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July 05, 2016.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management has been approved by the Board of Directors and initialed by us for identification purpose. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:




Office : 103, 1st Floor, City Center, Ashok Circle, Alwar-301001 (Rajasthan)
Phone : Office 0144 - 2340924, 7014347644
Mobile : 9414215353 (ML Agarwal)
E-mail : khetawatagarwal21@gmail.com

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended March 31, 2020 as well as the year to date results for the period from April 01, 2019 to March 31, 2020.



For Khetawat Agarwal & Co.
Chartered Accountants


M.L. Agarwal
Partner
M.N. 072854

Place: Jaipur

Date: June 19, 2020

UDIN: 20072854AAAAAM5192

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 19.06.2020

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Declaration pursuant to Regulation 33(3) (d) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir / Ma'am,

DECLARATION

We, Deepak Data, Managing Director and Himanshu Gupta, Chief Financial Officer of Sarda Proteins Ltd (CIN: L15142RJ1991PLC006353) having its Registered office situated at B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan) hereby declare that M/s Khetawat Agarwal & Co. (FRN: 003960C), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Audited Financial Results for the quarter and year ended on 31st March, 2020.

This declaration is given in compliance to Regulation 33(3)(d) of the Listing Regulations as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

You are requested to kindly take the same on record.

Thanking You,
Yours Faithfully

For Sarda Proteins Ltd

For SARDAPROTEINS LTD.


Director

Deepak Data
Managing Director
DIN: 01672415

For SARDAPROTEINS LTD.


CFO

Himanshu Gupta
Chief Financial Officer
PAN: ANMPG4020H